Prestige Consumer Healthcare (NYSE:PBH) VP Jeffrey Zerillo Sells 719 Shares of Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares in the company, valued at $2,539,740. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jeffrey Zerillo also recently made the following trade(s):

• On Monday, December 1st, Jeffrey Zerillo sold 281 shares of Prestige Consumer Healthcare stock. The shares were sold at an average price of $60.00, for a total value of $16,860.00.

Prestige Consumer Healthcare Stock Performance

PBH opened at $59.80 on Wednesday. The firm has a market capitalization of $2.88 billion, a P/E ratio of 14.04, a price-to-earnings-growth ratio of 1.93 and a beta of 0.39. The stock’s 50 day moving average price is $61.16 and its two-hundred day moving average price is $70.21. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a 12-month low of $57.25 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company had revenue of $274.11 million during the quarter, compared to analyst estimates of $257.14 million. During the same period in the previous year, the company earned $1.09 earnings per share. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PBH has been the topic of several research analyst reports. Jefferies Financial Group decreased their price target on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Wall Street Zen cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research note on Wednesday, September 24th. Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $85.33.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its stake in Prestige Consumer Healthcare by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock worth $161,723,000 after acquiring an additional 119,459 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after purchasing an additional 70,376 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Prestige Consumer Healthcare by 45.3% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock valued at $135,903,000 after purchasing an additional 493,199 shares during the last quarter. Geode Capital Management LLC boosted its position in Prestige Consumer Healthcare by 0.7% in the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after buying an additional 9,455 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after buying an additional 261,537 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.